Drug
Nivolumab
Data on this page refer exclusively to patients treated with
Nivolumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-PD-(L)1 mAb group page.
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Checkpoint Inhibitors |
| Group | Anti-PD-(L)1 mAb |
| Mechanism of Action | PD-(L)1 inhibitor |
| Half-life | 26,5 d |
Location
Treated site
